Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 30, 2025Cancer ScienceOpen Access

Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

TEToru EbinaMRMasaki RiYMYoshiaki Marumo

Discussion

Loading...

Member takes

Implication

Analysis reveals JAK–STAT1 pathway and IDO upregulation in multiple myeloma stromal cells, suggesting pharmacological interventions could enhance outcomes.

Key Points

  • Multiple myeloma cells increased IDO in stromal cells through cytokine signaling pathways, targeting therapy for better outcomes.
  • IDO was associated with poor prognosis in lenalidomide-treated refractory/relapsed multiple myeloma patients.
  • Analysis of co-culture systems showed phosphorylation of STAT1 and upregulation of IRF1 linked to IDO expression.
  • JAK inhibitors may disrupt IDO upregulation and improve the tumor microenvironment effectiveness in immunotherapy.

Cite This Study

Ebina et al. (2025) studied this question.

synapsesocial.com/papers/692b9da01d383f2b2a37a365https://doi.org/10.1111/cas.70255
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma2025
  2. 2IDO1 Inhibition Promotes Activation of Tumor-intrinsic STAT3 Pathway and Induces Adverse Tumor-protective Effects2024 · 4 citations
  3. 3Indole-related metabolites suppress the anti-tumor function of CD8+ T cells in the bone marrow microenvironment of multiple myeloma2025
  4. 4Tryptophan metabolism and the plasma cell/multiple myeloma microenvironment 39072025
  5. 5Tryptophan metabolism plays a significant role in multiple myeloma survival2025